Ever since the discovery of antibiotics in last century, irrational use of these ‘Miracle-drugs’ has led to the evolution of various types of antibiotic-resistance in microbes. Emergence of Multi-drug resistant (MDR) Extended Spectrum beta lactamase (ESBL), Carbapenemases, in particular Klebsiella pneumoniae Carbapenemase (KPC) and Methicillin-resistant Staphylococcus aureus (MRSA) has posed a serious roadblock in therapeutic management of immunocompromised patients. This devastating concern is further aggravated by drying antibiotic pipeline and non avialbility of newer and safer antibiotics in near future. It is estimated that each year around 4 million patients acquire a healthcare-associated infections and at least 25,000 people lost there lives in European Union (EU) alone. Health and economic consequences associated with MDR infections are immense and EU region alone spends around € 1.5 billion annually to combat these fatal infections. This unparallel expansion of MDR microbes is not restrcited to a single geographical location and no country can isolate itself from resistant pathogens. Although highest number of incidences for MDR infections are documented in industrialized nations but they pose greater potential for harm in the developing countries like India.
VMRC has recognised this global threat years ago and is a pioneer to work on AMR. Since past 12 years this advanced research centre has successfully developed a platform technology which promote novel use of already developed antibiotics to make them more effective on drug-resistant pathogens and break vicious resistance cycle. VMRC has succesfully patented a few adjuvants which when combined with existing antibiotics can potentiate the activity and break resistance. The biggest example of suuccessful use of this technology is ‘ELORES’ an Antibiotic Adjuvant Entity (AAE) which is effective against deadliest of ‘Superbugs’ such as Klebsiella pneumoniae, A.baumanii and NDM-1 along with other Multidrug Resistant ESBL/MBL producing gram negative microbes. ‘POTENTOX’ and ‘VANCOPLUS’ are other outstanding innovation products from VMRC to fight against MDR microbes in other resistance such as quinolone, gram postive resistance. VMRC also supports non-profit organisations and health care centres with the primary objective of promoting rational antibiotic usage and providing more safer, effective and economical antibiotics globally.